Green Cross To Focus On Biobetters As Korean Biosimilar Space Gets Crowded: Bio Korea Conference

SEOUL - Green Cross will turn its attention to "biobetters" in coming years such as its biobetter of Roche's oncology agent Herceptin (trastuzumab) being pursued now, Green Cross CEO Rhee Byung-Geon said during the Bio Korea 2010 conference in Seoul Sept. 1